Issue Date: November 6, 2017
Synthetic Genomics boosts RNA vaccines
Synthetic Genomics has formed two partnerships to pursue RNA replicon-based vaccines, in which self-replicating RNA molecules encode multiple antigen proteins to produce an immune response. One partner, Arcturus Therapeutics, will share its RNA delivery system for an undisclosed payment plus milestones and royalties. Arcturus and Janssen recently agreed to develop hepatitis B treatments with the RNA delivery technology. Synthetic Genomics will also partner with Ceva Santé Animale to develop livestock vaccines.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society